南方国证港股通创新药ETF今日起发售，募集上限20亿元
Zheng Quan Shi Bao Wang·2025-09-03 01:29
Group 1 - The Southern Guozheng Hong Kong Stock Connect Innovative Drug ETF (159297) will be launched for subscription from September 3 to September 12, 2025, with a maximum initial fundraising scale of 2 billion yuan [1] - The fund will be managed by Southern Fund, with Zhang Qisi and Ye Zhenan as fund managers [1] - The performance benchmark for the fund is the Guozheng Hong Kong Stock Connect Innovative Drug Index, adjusted for valuation exchange rates [1]